Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.…
Oragenics: Q3 Earnings Snapshot
Oragenics (NYSEAMERICAN: OGEN) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.
The shares were at 0.1570 USD on 20 November 2026, down 86.0% over 52 weeks. Its 52-week range is 0.1570 USD to 1.220 USD, and it trades at the bottom of that range.
Its market capitalisation is 708.38K USD.
Oragenics reports return on equity of -118.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.86M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.